Our study also demonstrated that combining Tug1‐siRNAs with Pdl1 checkpoint blockaders could enhance the antitumor response and offer a novel therapy to be tested in clinical trials with HCC patients. Here, TUG1 is linked to hepatocellular carcinoma.